Your browser doesn't support javascript.
loading
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
Takemura, Miki; Wise, Mark G; Hackel, Meredith A; Sahm, Daniel F; Yamano, Yoshinori.
Afiliación
  • Takemura M; Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
  • Wise MG; International Health Management Associates, Inc., Schaumburg, IL, USA.
  • Hackel MA; International Health Management Associates, Inc., Schaumburg, IL, USA.
  • Sahm DF; International Health Management Associates, Inc., Schaumburg, IL, USA.
  • Yamano Y; Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
J Antimicrob Chemother ; 78(8): 2019-2027, 2023 08 02.
Article en En | MEDLINE | ID: mdl-37390312
OBJECTIVES: To evaluate the in vitro antibacterial activity of cefiderocol, a siderophore cephalosporin against MBL-producing clinical isolates. METHODS: MBL-producing strains were selected from clinical isolates of Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii complex collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies from 2014 to 2019. MICs of cefiderocol and comparator agents were determined by the broth microdilution method according to the CLSI guideline. RESULTS: A total of 452 MBL-producing strains consisting of 200 Enterobacterales, 227 P. aeruginosa and 25 A. baumannii complex were identified. The highest number of MBL-producing Enterobacterales strains were detected in Greece. MBL-producing strains of both P. aeruginosa and A. baumannii complex were isolated most frequently in Russia. For Enterobacterales, 91.5% or 67.5% of MBL-producing strains had cefiderocol MIC values ≤4 mg/L (CLSI susceptibility breakpoint) or ≤2 mg/L (EUCAST susceptibility breakpoint), respectively. All MIC values of cefiderocol for MBL-producing P. aeruginosa strains were ≤4 mg/L (CLSI susceptibility breakpoint), and 97.4% of them had cefiderocol MIC values ≤2 mg/L (EUCAST susceptibility breakpoint). For A. baumannii complex, 60.0% or 44.0% of MBL-producing strains had cefiderocol MIC values ≤4 mg/L (CLSI susceptibility breakpoint) or ≤2 mg/L (EUCAST pharmacokinetic-pharmacodynamic susceptibility breakpoint), respectively. Against all types of MBL-producing strains, MIC distribution curves of cefiderocol were located in the lowest numerical values, compared with other ß-lactams and ß-lactam/ß-lactamase inhibitor combinations tested and ciprofloxacin. CONCLUSIONS: Although the types of MBL-producing strains isolated by country varied, cefiderocol showed potent in vitro activity against all types of MBL-producing Gram-negative bacteria regardless of the bacterial species.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cefalosporinas / Antibacterianos Tipo de estudio: Guideline / Screening_studies País/Región como asunto: Europa Idioma: En Revista: J Antimicrob Chemother Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cefalosporinas / Antibacterianos Tipo de estudio: Guideline / Screening_studies País/Región como asunto: Europa Idioma: En Revista: J Antimicrob Chemother Año: 2023 Tipo del documento: Article País de afiliación: Japón
...